NeuroOne Q3 FY2026 revenue up 16% to $2.0M; gross margin 59.9%, net loss $2.0M

NEUROONE MEDICAL TECHNOLOGIES Corp

Product revenue $2.0M, +16% YoY; product gross margin 59.9% vs 53.9% (record).
New product orders $2.7M in Q3, +43% YoY; backlog $1.7M; FY2026 orders $11.2M.
Net loss $2.0M ($0.23 basic, $0.28 diluted) vs $1.5M loss prior year; cash $2.0M.
Received ISO 13485 certification; StereoCED platform expected by end FY2026 for research/IDE studies.
Lead investor raised stake from 7.4% to 12.5% post-quarter; raised $1.0M via ATM on July 13.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.